Monte Rosa Therapeutics (GLUE)
(Delayed Data from NSDQ)
$3.94 USD
-0.04 (-1.01%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $3.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
GLUE 3.94 -0.04(-1.01%)
Will GLUE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GLUE
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
GLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
Other News for GLUE
Monte Rosa Therapeutics GAAP EPS of -$0.43, revenue of $4.7M
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
TD Cowen Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics: Q2 Earnings Snapshot
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update